Given the heightened expression of CYSLTR1 in psoriatic lesions and the capacity of montelukast to restrain Th17 and IL-17, montelukast holds promise as a therapeutic agent for managing psoriasis characterized by hyperactive Th17 cells. Here, IL17A is linked to psoriasis.